Second-quarter net revenues from Imbruvica were $850 million, up 35.6% year over year. U.S. sales of Imbruvica grossed $693 million, up 31.1% from the year-ago figure. AbbVie logged $157 million of international profit sharing with J&J. Strong patient uptake including higher market share and growth across multiple indications, particularly CLL led to the strong performance of Imbruvica. In 2018, Imbruvica global revenues are expected to exceed $3.4 billion (previously $3.3 billion) with sales in the United States likely to cross $2.8 billion (previously $2.7 billion).